07:00 , Sep 30, 2013 |  BC Week In Review  |  Company News

Progenics, ITM Isotope Technologies Munich AG deal

Progenics granted ITM exclusive rights to manufacture and market Onalta edotreotide to treat cancer. ITM received worldwide rights except for Albania, Algeria, Bahrain, Bulgaria, Cyprus, Greece, Iran, Iraq, Kuwait, Lebanon, Oman, Qatar, Romania, Saudi Arabia,...
07:00 , Sep 14, 2009 |  BC Week In Review  |  Company News

BioMedica Life Sciences S.A., Molecular Insight deal

BioMedica received an exclusive license to develop and commercialize Molecular Insight's Onalta edotreotide in certain countries in Europe, the Middle East, North Africa, Russia and Turkey. The yttrium-90 radiolabeled somatostatin peptide analog has completed Phase...